anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Silicone oil has been used as a surgical tool in retinal detachment surgery since 1962. The National Eye Institute Silicone Study demonstrated the superiority of silicone oil compared with sulfur hexafluoride, and its comparability with perfluoropropane, for the treatment of complicated retinal detachment associated with advanced proliferative vitreoretinopathy. There are some complications occurring in pars plana vitrectomy with silicone oil tamponade. These complications may occur during surgery and after the surgery. Silicone oil emulsification is one of the complication that may result in severe sequels including band-shaped keratopathy, complicated glaucoma and retinopathy that are difficult to treat. The commonly used silicone oil includes low viscosity and high viscosity type. It is believed that low viscosity silicone oil has more risk to develop emulsification than high viscosity silicone oil. Up to now, however, there is no conclusive guideline that which types of silicone oil is suitable for these complicated retinal detachment surgeries and what is the appropriate time to remove the oil. Retrospective medical review of these patients using 1000-vs 5000-centistoke silicone oil demonstrated that anatomic and visual acuity outcomes, as well as complication rates including emulsification, were similar in both groups. To the best of authors' knowledge, there has been no prospective study on this subject. This study aims to study the silicone oil emulsification comparing between low viscosity and high viscosity silicone oil after complicated retinal detachment surgery.
PURPOSE:To allow elusion of a medicine to continue by floating a preparation in gastric juice. CONSTITUTION:This invented floatable preparation contains at least a porous cellulose and chemicals such as a medicine and can float in water for >=30 min. The medicine may be supported on the porous cellulose, or the porous cellulose may be coated with a film containing the medicine. After coating the porous cellulose with a coating film for giving an excellent floatability, the medicine may be supported thereon. The above-mentioned porous cellulose may be coated with a medicine-containing film. The medicine may be used together with an additive such as a binder. This floatable preparation may be used in a solid dosage form such as powder, granule, tablet or capsule.
Individuals belonging to Group 2 received a bottle containing aromatic gel enriched with ylang ylang essence only in 2% concentration and used massage with essential oil 3 times a day: leaving home to go to work, leaving the shift and before bedtime. The points indicated were the two handles and the sternum. Gel was applied and massaged in a circular motion for 30 seconds.
The CARB diet will be a low-fat diet where cheese is replaced by starchy carbohydrates and lean meat. The CARB diet will have the same protein content (15 E%) and quality as the CHEESE and MEAT diet but a lower fat content (approx. 25 E%) and a correspondingly higher carbohydrate content (approx. 60 E%).
Provided are methods comprising presenting a sensory environment to an individual experiencing the effects of a psychoactive agent, monitoring the neural status, the physiological status, or both, of the individual, and presenting a modified sensory environment to the individual based on the monitoring. In certain embodiments, the agent is a psychedelic agent. According to some embodiments, presenting a sensory environment to the individual comprises presenting to the individual a visual stimulus, an auditory stimulus, a tactile stimulus, an olfactory stimulus, or any combination thereof. In certain embodiments, presenting a modified sensory environment to the individual comprises presenting a customized sensory environment to the individual in real-time based on the monitoring. In some embodiments, the individual is suffering from a mental health condition selected from depression, anxiety, post-traumatic stress disorder (PTSD), addiction, and any combination thereof. Systems that find use in practicing the methods of the present disclosure are also provided.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Approximately 1500 patients with RMS received KESIMPTA in clinical studies. In Study 1 and Study 2, 1882 patients with RMS were randomized, 946 of whom were treated with KESIMPTA for a median duration of 85 weeks; 33% of patients receiving KESIMPTA were treated for up to 120 weeks [see Clinical Studies (14.1)]. The most common adverse reactions occurring in greater than 10% of patients treated with KESIMPTA and more frequently than in patients treated with teriflunomide were upper respiratory tract infections, injection-related reactions (systemic), headache, and injection-site reactions (local). The most common cause of discontinuation in patients treated with KESIMPTA was low immunoglobulin M (3.3%), defined in trial protocols as IgM at 10% below the lower limit of normal (LLN).

Table 1 summarizes the adverse drug reactions that occurred in Study 1 and Study 2.

Injection-Related Reactions and Injection-Site Reactions

The incidence of injection-related reactions (systemic) was highest with the first injection (14.4%), decreasing with subsequent injections (4.4% with second, less than 3% with third injection). Injection-related reactions were mostly (99.8%) mild to moderate in severity. Two (0.2%) patients treated with KESIMPTA reported serious injection-related reactions. There were no life-threatening injection-related reactions. Most frequently reported symptoms (2% or greater) included fever, headache, myalgia, chills, and fatigue.

In addition to systemic injection-related reactions, local reactions at the administration site were very common. Local injection-site reactions were all mild to moderate in severity. The most frequently reported symptoms (2% or greater) included erythema, pain, itching, and swelling [see Warnings and Precautions (5.2)].

Laboratory Abnormalities

Immunoglobulins

In Study 1 and Study 2, a decrease in the mean level of IgM was observed in KESIMPTA-treated patients but was not associated with an increased risk of infections [see Warnings and Precautions (5.3)]. In 14.3% of patients in Study 1 and Study 2, treatment with KESIMPTA resulted in a decrease in a serum IgM that reached a value below 0.34 g/L. KESIMPTA was associated with a decrease of 4.3% in mean IgG levels after 48 weeks of treatment and an increase of 2.2% after 96 weeks.
Swabbing infants born by C-section with a gauze incubated in the maternal vagina about an hour before the C-section. The gauze will be extracted prior to the C-section, kept in a sterile container in an incubator (37 ℃), and taken out from the incubator immediately before the swabbing. The infant will be swabbed with the gauze, starting from the lips, followed by the face, thorax, arms, legs, genitals and anal region, and finally the back. The swabbing will take around 15-20 seconds.
OBJECTIVE: To determine the efficacy of femoral neck system compared to dynamic hip screws in treating femoral neck fractures.
METHODS: The systematic review was conducted from January to March 2023, and comprised literature search on PubMed, Embase, Scopus, Ovid, Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure and Wanfang databases for relevant studies published up to March 1, 2023. Study data as well as demographic and outcome parameters related to the patients were extracted, and the methodological index for non-randomised studies was used to assess the risk of bias. Review Manager software was used to conduct metaanalysis.
RESULTS: Of the 567 studies initially found, 6(1%) were included, with the publication date ranging from August 2021 to February 2023. There were 5(83.3%) studies published in English and 1(16.7%) in Chinese. Of the 577 patients with femoral neck fractures, 287(49.7%) were treated with femoral neck system and 290(50.3%) with dynamic hip screws. Significant differences were shown between the two groups regarding operation duration, blood loss, internal fixation failure rate and Harris hip score (p=<0.05). There was no significant differences between the groups regarding time from injury to surgery, hospitalisation, complication rate and femoral neck shortening rate (p>0.05).
CONCLUSION: The novel femoral neck system could optimise surgical procedures, with shorter operation times and lesser blood loss. The femoral neck system and dynamic hip screws were comparable in terms of complication rates and postoperative hip function.
All UC patients treated with CyA in Tampere University Hospital between 2009 and 2018 were reviewed from patient records and analyzed. Amelioration of UC was defined as clinical response for rescue therapy with no need for colectomy or third-line rescue therapy at the same hospitalization as index flare. Relapse was defined as requiring further Cs treatment, re-hospitalization, biologicals, small molecules, or colectomy later in follow-up. Patients were followed-up from the date of index flare until colectomy, death, or the end of observation period. Adverse events related to treatment were assessed throughout the duration of treatment. Surgical complications were defined by using Clavien-Dindo classification (grade III-V classified as severe complications). The surgical complications in Cyclosporine-treated patients were compared to all patients operated for treatment refractor UC in Tampere University Hospital within the same follow-up period.
INTRODUCTION: Migraine is a neurological disease that affects proportionally more women. It has been documented that migraineurs often experience balance disturbances.
OBJECTIVE: To evaluate the balance between migraineur patients (MG) and healthy volunteers classified as control group (CG).
METHOD: A cross-sectional study. Seventy-four women were evaluated: 37 MG and 37 CG. The evaluation of the center of pressure (COP) variables was carried out using a balance platform in three postures, bipodal eyes closed (BEC), right monopodal with eyes open (RMEO), and left monopodal with eyes open (LMEO). Self-report questionnaires (dizziness handicap inventory (DHI), fall risk efficacy scale (FES I), the functional impact scale (HIT 6) and the timed up and go test (TUG test) were used. The U-Mann Whitney test was used to verify differences in the COP between MG and CG. The Kruskal-Wallis one-way ANOVA was used to analyze the differences between migraine groups (MGs) with postures, self-report questionnaires, and TUG test. A p < 0.05 was considered statistically significant.
RESULTS: No statistically significant changes were found in the balance variables, except the medial-lateral excursion variable in the BEC (p < 0.02) and LMEO (p = 0.04) postures. No significant differences were found between the MGs with HIT 6 (p = 0.48) or FES I (p = 0.49). Significant differences were found between the MGs with DHI (p = 0.003). The TUG test showed statistically significant changes between groups (p < 0.01).
CONCLUSION: The women with migraine in this sample did not show differences in postural balance, however, dizziness and functional differences are shown compared to healthy women.
Participants will be enrolled at approximately 4 months after the start of TB treatment, entering the study directly into Step 2, and will be randomized to receive ID93 + GLA-SE immediately. They have no Step 1 observation period from the start of SOC TB treatment to randomization.
This is an observational post-market study. Women will be screened for participation where the decision to undergo prophylactic R-NSM surgery has already been made as part of their medical care. In order for women to be enrolled, surgeons must perform the surgery according to the Instructions For Use (IFU) of da Vinci Xi/X Surgical System. Women will sign an informed consent form for their participation in the study. Women will be prospectively followed at 6 weeks, 3 months and 1 year post-surgery, which is within the standard of care. Data will be collected prospectively from the medical records and women will be asked to complete preoperative and postoperative questionnaires.
In severe pre-eclampsia or eclampsia, the total initial dose is 10 to 14 g of magnesium sulfate. Intravenously, a dose of 4 to 5 g in 250 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP may be infused. Simultaneously, IM doses of up to 10 g (5 g or 10 mL of the undiluted 50% solution in each buttock) are given. Alternatively, the initial IV dose of 4 g may be given by diluting the 50% solution to a 10 or 20% concentration; the diluted fluid (40 mL of a 10% solution or 20 mL of a 20% solution) may then be injected IV over a period of three to four minutes. Subsequently, 4 to 5 g (8 to 10 mL of the 50% solution) are injected IM into alternate buttocks every four hours as needed, depending on the continuing presence of the patellar reflex and adequate respiratory function. Alternatively, after the initial IV dose, some clinicians administer 1 to 2 g/hour by constant IV infusion. Therapy should continue until paroxysms cease. A serum magnesium level of 6 mg/100 mL is considered optimal for control of seizures. A total daily (24 hr) dose of 30 to 40 g should not be exceeded. In the presence of severe renal insufficiency, the maximum dosage of magnesium sulfate is 20 grams/48 hours and frequent serum magnesium concentrations must be obtained. Continuous use of magnesium sulfate  
in pregnancy beyond 5 to 7 days can cause fetal abnormalities.
<P>PROBLEM TO BE SOLVED: To provide dosage formulations including microparticles which provide enhanced images of long duration, and to provide a kit for administering the dosage formulations including the microparticles for use in the ultrasound imaging technology.  <P>SOLUTION: Clinical studies have been conducted and specific dosage formulations have been developed which provides significantly enhanced images of long duration by using polymeric microparticles. The polymeric microparticles have incorporated therein perfluorocarbon gases. The dosage formulation includes microparticles formed of a biocompatible polymer, preferably including a lipid incorporated therein, and containing a perfluorocarbon that is a gas at body temperature. The microparticles are provided to a patient in an amount effective to enhance ultrasound imaging in the cardiac ventricle for more than 5 minutes or in the myocardium for more than a minute, (in a dose ranging from 0.025 to 8.0 mg microparticles/kg body weight).  <P>COPYRIGHT: (C)2011,JPO&INPIT
Patients will undertake a series of exercise positions with the arm elevated above shoulder level with a stimulus applied with a weight and resistance band- such that the glenohumeral joint is exposed to a perturbed stimulus and has to utilise proprioception and motor control to correct arm position. The exercise session will be 45mins in length and occur once per week for 6 weeks.
The invention relates to a spraying pellicle capable of being used in high-temperature high-dampness environment and a preparation method thereof. The spraying pellicle comprises matrix and a drug; wherein the matrix is composed of poloxamer, ethanol, a thickening agent, and water. The provided spraying pellicle is in a liquid state at a room temperature or a high temperature (40 DEG C). The spraying pellicle can be sprayed over the human skin, and rapidly forms a membrane on the skin. The provided spraying pellicle is easy to carry along. The shortage that the conventional temperature-sensitive gel can only be used at a low temperature is overcome, and the application range of the spraying pellicle is enlarged. Furthermore, all temperature-sensitive materials and drugs can be made into the spraying pellicle.
1,099,066. Forming microcapsules. NATIONAL CASH REGISTER CO. July 8, 1966 [Aug. 18, 19651, No. 30800/66. Heading B8C. Minute particles or droplets of material are encapsulated in a hydrophobic film-forming polymer by dispersing them in a polymer wherein an adjustment of temperature causes separation into or formation of during dissolving rich and less rich polymer phases, the former of which coats the material with the polymer, no additional chemical phase separator being necessary. The process permits recovery of the solvent by re-cycling. The solvent is organic and " poor " i.e. effective at higher than at lower temperatures. A suitable pair of a polymer and a solvent or solvent mixture is selected, e.g. an ethyl cellulose and cyclohexane. The polymer is dissolved in the solvent with heating as necessary and the solution temperature lowered, or the polymer and solvent are heated, until two phases of solution are formed, of which the more voluminous has the lower polymer concentration, and acts as a vehicle for the other polymer rich phase, which is dispersed throughout it in droplet form by agitation. The particles of encapsulable material, e.g. aspirin, various inorganic salts, amphetamine sulphate, gelatin, a range of organic compounds or aqueous solutions which are added before or after temperature adjustment, become coated with the polymer-rich phase material. The walls harden by solvent loss as the temperature lowers further.
Disclosed are vaccine compositions for use in developing protective immunity against infection by Plasmodium parasites. Soluble proteinaceous immunogens are isolated from the fluid culture medium of in vitro propagated plasmodial species parasites (e.g., P.falciparum) in mammalian erythrocyte culture supernatant or from washes, including hypotonic washes, of cultured erythrocytes parasitized by plasmodium. Immunogens so obtained have molecular weights in the range from about 35,000 daltons to about 85,000 daltons. Two principal immunogens of the invention have molecular weights of about 42,000 and 54,000 daltons, respectively. The water soluble immunogens are administered in a suitable carrier such as isotonic salt solution and in combination with a suitable adjuvant such as saponin or, preferably, aluminum hydroxide. Upon administration to vertebrate animals susceptible to plasmodial infection, vaccines according to the invention provoke immune responses protective against morbidity and mortality caused by, e.g., P.falciparum infection. Disclosed also are procedures for optimization of large scale plasmodial parasite growth in human erythrocyte cultures with accompanying development of late erythrocytic stage parasites in large numbers and optimization of isolatable quantities of culture medium supernatant and wash-derived immunogens.
Some patients present with clinical symptoms of localized tenderness and pain associated with a specific peripheral nerve, such as the ulnar nerve at the elbow or the sciatic nerve, which has been called, although rarely, "Valleix point" or "Valleix phenomenon". The purpose of this article was to translate and research the 719-page book "Traité des névralgies ou affections douloureuses des nerfs" dated 1841, dedicated solely to nerve pain (neuralgia), written by the French physician François Louis Isidore Valleix (1807-1855). He may have been the first person to observe and describe this phenomenon of localized pain, but he was probably also the first to describe distal nerve radiation, which he called "élancement" or lancinating, or stabbing. He described the phenomenon of a nerve producing pain at points along its course that we now understand to be sites of compression, clearly describing cubital and fibular tunnel syndromes, which he called neuralgias. He also described some rarer sites of compression, such as supraorbital and occipital neuralgia, notalgia paresthetica, and ACNES, but he did not describe the most common site of compression today, the median nerve at the wrist. Valleix's descriptions are clear and precede the classic 1915 reports of Hoffmann's and Tinel's signs by 74 years.
PROBLEM TO BE SOLVED: To obtain the subject functional agent having excellent compatibility with various synthetic resins, etc., excellent processability, heat stability, bleed resistance, etc., useful as an antioxidant, etc., by reacting a specific functional agent with a specified polymer. SOLUTION: A functional agent containing a reactive group [e.g. 3-(3',5'-di-t- butyl-4'-hydroxyphenyl)propionic acid] is reacted with a polymer containing a group to be reacted with the reactive group to give the objective functional agent being an antioxidant, ultraviolet light absorber, light stabilizer, infrared light absorber and/or antistatic agent. Preferably the reaction temperature is generally 80 deg.C to the boiling point of a reaction solvent and the reaction time is generally 2-10 hours. The polymer part is preferably at least one kind selected from the group consisting of a polyolefin-based polymer, a polyether- based polymer, a polyester-based polymer, etc. The reaction is preferably a condensation reaction between a hydroxyl group and a carboxyl group or carboxyl chloride.
INTRODUCTION: Pulmonary ischemia-reperfusion (IR) injury (IRI) plays a significant role in various lung disorders and is a key factor in the development of primary graft dysfunction following lung transplantation. Hemopexin (Hx) is the major serum scavenger protein for heme, which is a prooxidant and pro-inflammatory compound. In the current study, we hypothesized that Hx could confer beneficial effects in sterile inflammation induced by IR-mediated lung injury.
METHODS: To examine this hypothesis, we administered Hx in an experimental mouse model of unilateral lung IRI.
RESULTS: Our results demonstrate that treatment with Hx alleviated histopathological signs of inflammation in ischemic lungs, as evidenced by a reduction in the number of infiltrating neutrophils and decreased levels of perivascular edema. In addition, thrombotic vaso-occlusion in pulmonary blood vessels of IRI lungs was reduced by Hx. Immunohistochemical analysis revealed that Hx inhibited the up-regulation of heme oxygenase-1, an enzyme highly induced by heme, in ischemic lungs. Finally, Hx administration caused a decrease in the levels of circulating B- and CD8+ T-lymphocytes in the peripheral blood of mice with pulmonary IRI.
CONCLUSION: These findings suggest that the serum heme scavenger protein Hx holds therapeutic promise in alleviating lung IRI-mediated sterile inflammation. Thus, Hx may represent a preemptive therapeutic approach in IR-related lung disorders such as primary graft dysfunction in lung transplantation.